Track Immix Biopharma Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immix Biopharma Inc. Common Stock IMMX · Stock Open Immix Biopharma Inc. Common Stock in new tab

7.84 USD
EPS
-0.83
P/B
1.96
ROE
-26.95
Beta
0.29
Target Price
23.80 USD
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-0.83
Book Value4.00
Price to Book1.96
Debt/Equity0.29
% Insiders14.845%
Estimates
Forward P/E-8.30
Forward EPS-0.95
Target Mean Price23.80

DCF valuation

Model fair value for Immix Biopharma Inc. Common Stock (IMMX)
Result
Sign in to run the valuation for IMMX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 23.80 USD (low 17.40, high 30.00)
Low 17.40
Mean 23.80
High 30.00
Price 7.84
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Immix Biopharma Inc. Common Stock Logo Immix Biopharma Inc. Common Stock Analysis (IMMX)

United States Health Care Official Website Stock

Is Immix Biopharma Inc. Common Stock a good investment? Immix Biopharma Inc. Common Stock (IMMX) is currently trading at 7.84 USD. Market analysts have a consensus price target of 23.80 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immix Biopharma Inc. Common Stock is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -0.95.

Investor FAQ

Does Immix Biopharma Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immix Biopharma Inc. Common Stock?

Immix Biopharma Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -0.83.

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Exchange Ticker
NMS (United States) IMMX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion